Table 2 Effects of the H51Y and R263K mutations on HIV replication capacity and susceptibility to dolutegravir (DTG), raltegravir (RAL), and elvitegravir (EVG) as measured by the PhenoSense® Integrase assay (Monogram Biosciences)
From: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
DTG | RAL | EVG | Replication capacity | ||
|---|---|---|---|---|---|
Backbone | Genotype | Fold change | Fold change | Fold change | |
pNL4-3 | WT | 0.92 | 0.91 | 1.03 | 100% |
H51Y | 1.25 | 1.11 | 2.06 | 89% | |
R263K | 1.95 | 1.21 | 3.28 | 70% | |
H51Y/R263K | 6.95 | 2.94 | 41.5 | 11% |